Oncolytics Biotech Inc T.ONC

Merck's keytruda snags 5th approval in single cancer - NSCLC

[Noteable]

If Merck (MSD) can have its 5th approval by the FDA in a single cancer (NSCLC), ask yourself how many indications ONCY's can have approved in metastatic breast cance for example. 2, 3, 4 or more? And then how many more in pancreatic cancer, and then colorectal cancer (msCRC), etc.

" A PD-1 checkpoint inhibitor, Keytruda is Merck’s top-performing asset, earning more than $15 billion in year-to-date revenue by the end of Q3, 2022. Aside from NSCLC, the drug is also approved for Hodgkin lymphoma, melanoma, colorectal cancer, cervical cancer, breast cancer and hepatocellular carcinoma, among several other indications."

https://www.biospace.com/article/merck-s-keytruda-snags-fifth-nsclc-nod/

[Noteable]

January 27, 2023 - "Merck & Co.’s Keytruda has long been viewed as a standard of care in metastatic non-small cell lung cancer (NSCLC). Now, the PD-1 king has scored the FDA’s permission to enter early-stage disease with an approval that trumps Roche’s Tecentriq.   The FDA has cleared Keytruda for use after surgery and chemotherapy for early NSCLC across stages 1B, 2 or